The Experts below are selected from a list of 111 Experts worldwide ranked by ideXlab platform
Bo Mu - One of the best experts on this subject based on the ideXlab platform.
-
screening of multiple myeloma by polyclonal rabbit anti human Plasmacytoma Cell immunoglobulin
PLOS ONE, 2013Co-Authors: Bo Mu, Huan Zhang, Junbao Yang, Yuewu Shen, Baofeng Chen, Suhua LiangAbstract:Antibody-based immunotherapy has been effectively used for tumor treatment. However, to date, only a few tumor-associated antigens (TAAs) or therapeutic targets have been identified. Identification of more immunogenic antigens is essential for improvements in multiple myeloma (MM) diagnosis and therapy. In this study, we synthesized a polyclonal antibody (PAb) by immunizing rabbits with whole human Plasmacytoma ARH-77 Cells and identified MM-associated antigens, including enlonase, adipophilin, and HSP90s, among others, via proteomic technologies. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that 200 µg/mL PAb inhibits the proliferation of ARH-77 Cells by over 50% within 48 h. Flow cytometric assay indicated that PAb treatment significantly increases the number of apoptotic Cells compared with other treatments (52.1% vs. NS, 7.3% or control rabbit IgG, 9.9%). In vivo, PAb delayed tumor growth and prolonged the lifespan of mice. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed that PAb also induces statistically significant changes in apoptosis compared with other treatments (P<0.05). We therefore conclude that PAb could be used for the effective screening and identification of TAA. PAb may have certain anti-tumor functions in vitro and in vivo. As such, its combination with proteomic technologies could be a promising approach for sieving TAA for the diagnosis and therapy of MM.
-
polyclonal rabbit anti murine Plasmacytoma Cell globulins induce myeloma Cells apoptosis and inhibit tumour growth in mice
Apoptosis, 2011Co-Authors: Bo Mu, Jinliang Yang, Yan Zhou, Zhihui Cheng, Zhiyong Li, Fei LengAbstract:Multiple myelomas (MMs) are etiologically heterogeneous and there are limited treatment options; indeed, current monoclonal antibody therapies have had limited success, so more effective antibodies are urgently needed. Polyclonal antibodies are a possible alternative because they target multiple antigens simultaneously. In this study, we produced polyclonal rabbit anti-murine Plasmacytoma Cell immunoglobulin (PAb) by immunizing rabbits with the murine Plasmacytoma Cell line MPC-11. The isolated PAb bound to plasma surface antigens in several MM Cell lines, inhibited their proliferation as revealed by MTT assay, and induce apoptosis as indicated by flow cytometry, microscopic observation of apoptotic changes in morphology, and DNA fragmentation on agarose gels. The cytotoxicity of PAb on MPC-11 Cell lines was both dose-dependent and time-dependent; PAb exerted a 50% inhibitory effect on MPC-11 Cell viability at a concentration of 200 µg/ml in 48 h. Flow cytometry demonstrated that PAb treatment significantly increased the number of apoptotic Cells (48.1%) compared with control IgG (8.3%). Apoptosis triggered by PAb was confirmed by activation of caspase-3, -8, and -9. Serial intravenous or intraperitoneal injections of PAb inhibited tumour growth and prolonged survival in mice bearing murine Plasmacytoma, while TUNEL assay demonstrated that PAb induced statistically significant apoptosis (P < 0.05) compared to control treatments. We conclude that PAb is an effective agent for in vitro and in vivo induction of apoptosis in multiple myeloma and that exploratory clinical trials may be warranted.
Mark P. Hedger - One of the best experts on this subject based on the ideXlab platform.
-
A sensitive and specific in vitro bioassay for activin using a mouse Plasmacytoma Cell line, MPC-11
Journal of Endocrinology, 1999Co-Authors: David James Phillips, Julie Brauman, Aj Mason, D. M. De Kretser, Mark P. HedgerAbstract:A new in vitro bioassay for activin was developed using the mouse Plasmacytoma Cell line, MPC-11. Human recombinant (hr) activin A dose-dependently inhibited the proliferation of these Cells, whereas a range of other factors, including inhibin, follistatin and transforming growth factor-‚1, -‚2 and -‚3 had no eVect. Conditioned medium containing activin B induced an inhibition similar to hr-activin A. The inhibitory influence of activin A could be blocked by follistatin, but not by hr-inhibin A. This bioassay had a sensitivity for activin A of around 0·4 ng/ml, an ED50 response of 3·5 ng/ml, and an intraassay coeYcient of variation of
-
a sensitive and specific in vitro bioassay for activin using a mouse Plasmacytoma Cell line mpc 11
Journal of Endocrinology, 1999Co-Authors: David James Phillips, Julie Brauman, Aj Mason, D. M. De Kretser, Mark P. HedgerAbstract:A new in vitro bioassay for activin was developed using the mouse Plasmacytoma Cell line, MPC-11. Human recombinant (hr) activin A dose-dependently inhibited the proliferation of these Cells, whereas a range of other factors, including inhibin, follistatin and transforming growth factor-‚1, -‚2 and -‚3 had no eVect. Conditioned medium containing activin B induced an inhibition similar to hr-activin A. The inhibitory influence of activin A could be blocked by follistatin, but not by hr-inhibin A. This bioassay had a sensitivity for activin A of around 0·4 ng/ml, an ED50 response of 3·5 ng/ml, and an intraassay coeYcient of variation of <11%. It oVers substantial advantages over existing in vitro activin bioassays in terms of ease of use, specificity and throughput. The utility of the MPC-11 bioassay was demonstrated in the purification of activin from amniotic fluid, where an almost identical profile of bioactive activin A was detected compared with the pituitary Cell bioassay of activin. Bioactive activin could also be detected in unpurified ovine allantoic and amniotic fluids and bovine follicular fluid. Measuring activin in untreated and heat-treated human sera or seminal plasma was hampered by a non-specific inhibitory eVect, so that several serum samples did not run parallel with the hr-activin A standard. This inhibitory eVect by serum could not be overcome by addition of follistatin, suggesting it is not activin-like bioactivity. This new bioassay for activin demonstrates widespread applicability for monitoring of purified or partially purified samples during purification procedures, bioactivity measurements, receptor-binding studies and assays of Cell culture medium.
Fei Leng - One of the best experts on this subject based on the ideXlab platform.
-
polyclonal rabbit anti murine Plasmacytoma Cell globulins induce myeloma Cells apoptosis and inhibit tumour growth in mice
Apoptosis, 2011Co-Authors: Bo Mu, Jinliang Yang, Yan Zhou, Zhihui Cheng, Zhiyong Li, Fei LengAbstract:Multiple myelomas (MMs) are etiologically heterogeneous and there are limited treatment options; indeed, current monoclonal antibody therapies have had limited success, so more effective antibodies are urgently needed. Polyclonal antibodies are a possible alternative because they target multiple antigens simultaneously. In this study, we produced polyclonal rabbit anti-murine Plasmacytoma Cell immunoglobulin (PAb) by immunizing rabbits with the murine Plasmacytoma Cell line MPC-11. The isolated PAb bound to plasma surface antigens in several MM Cell lines, inhibited their proliferation as revealed by MTT assay, and induce apoptosis as indicated by flow cytometry, microscopic observation of apoptotic changes in morphology, and DNA fragmentation on agarose gels. The cytotoxicity of PAb on MPC-11 Cell lines was both dose-dependent and time-dependent; PAb exerted a 50% inhibitory effect on MPC-11 Cell viability at a concentration of 200 µg/ml in 48 h. Flow cytometry demonstrated that PAb treatment significantly increased the number of apoptotic Cells (48.1%) compared with control IgG (8.3%). Apoptosis triggered by PAb was confirmed by activation of caspase-3, -8, and -9. Serial intravenous or intraperitoneal injections of PAb inhibited tumour growth and prolonged survival in mice bearing murine Plasmacytoma, while TUNEL assay demonstrated that PAb induced statistically significant apoptosis (P < 0.05) compared to control treatments. We conclude that PAb is an effective agent for in vitro and in vivo induction of apoptosis in multiple myeloma and that exploratory clinical trials may be warranted.
Geoffrey Brown - One of the best experts on this subject based on the ideXlab platform.
-
Persistent growth of BALB/C mouse Plasmacytoma and human myeloma Cell lines in the presence of phorbol myristate acetate is associated with continued expression of Lap18 (stathmin).
Hematological Oncology, 2007Co-Authors: N A Jones, D C Rowlands, W E B Johnson, Ian C M Maclennan, Geoffrey BrownAbstract:: Lap18 is a highly conserved cytosolic protein that is expressed in dividing Cells. Data from a number of studies show that a range of Cell lines and mitogen-stimulated normal Cells cultured in PMA phosphorylate and subsequently down-regulate Lap18. This has been found to be associated with growth arrest, although it is not clear that these events are causally related. In the present study we confirm that the HL60 promyelocytic leukemia and K562 erythroleukemia Cell lines, when cultured with PMA, behave in this manner. This was not the case for any of five mouse Plasmacytoma Cell lines and six lines derived from patients with multiple myeloma or plasma Cell leukemia. All of these lines contain Lap18, although the level of this protein in the mouse but not the human Plasmacytoma Cell-line Cells is relatively low. All the neoplastic plasma Cell-line Cells phosphorylate Lap18 on culture with PMA, but this does not induce growth arrest nor result in down-regulation of Lap18 expression. Further experiments are required to test whether there is a mechanistic relationship between the continued growth of Plasmacytoma Cell lines and their failure to down-regulate Lap18 on culture in PMA.
-
persistent growth of balb c mouse Plasmacytoma and human myeloma Cell lines in the presence of phorbol myristate acetate is associated with continued expression of lap18 stathmin
Hematological Oncology, 1995Co-Authors: N A Jones, D C Rowlands, W E B Johnson, Ian C M Maclennan, Geoffrey BrownAbstract:: Lap18 is a highly conserved cytosolic protein that is expressed in dividing Cells. Data from a number of studies show that a range of Cell lines and mitogen-stimulated normal Cells cultured in PMA phosphorylate and subsequently down-regulate Lap18. This has been found to be associated with growth arrest, although it is not clear that these events are causally related. In the present study we confirm that the HL60 promyelocytic leukemia and K562 erythroleukemia Cell lines, when cultured with PMA, behave in this manner. This was not the case for any of five mouse Plasmacytoma Cell lines and six lines derived from patients with multiple myeloma or plasma Cell leukemia. All of these lines contain Lap18, although the level of this protein in the mouse but not the human Plasmacytoma Cell-line Cells is relatively low. All the neoplastic plasma Cell-line Cells phosphorylate Lap18 on culture with PMA, but this does not induce growth arrest nor result in down-regulation of Lap18 expression. Further experiments are required to test whether there is a mechanistic relationship between the continued growth of Plasmacytoma Cell lines and their failure to down-regulate Lap18 on culture in PMA.
Suhua Liang - One of the best experts on this subject based on the ideXlab platform.
-
screening of multiple myeloma by polyclonal rabbit anti human Plasmacytoma Cell immunoglobulin
PLOS ONE, 2013Co-Authors: Bo Mu, Huan Zhang, Junbao Yang, Yuewu Shen, Baofeng Chen, Suhua LiangAbstract:Antibody-based immunotherapy has been effectively used for tumor treatment. However, to date, only a few tumor-associated antigens (TAAs) or therapeutic targets have been identified. Identification of more immunogenic antigens is essential for improvements in multiple myeloma (MM) diagnosis and therapy. In this study, we synthesized a polyclonal antibody (PAb) by immunizing rabbits with whole human Plasmacytoma ARH-77 Cells and identified MM-associated antigens, including enlonase, adipophilin, and HSP90s, among others, via proteomic technologies. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that 200 µg/mL PAb inhibits the proliferation of ARH-77 Cells by over 50% within 48 h. Flow cytometric assay indicated that PAb treatment significantly increases the number of apoptotic Cells compared with other treatments (52.1% vs. NS, 7.3% or control rabbit IgG, 9.9%). In vivo, PAb delayed tumor growth and prolonged the lifespan of mice. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed that PAb also induces statistically significant changes in apoptosis compared with other treatments (P<0.05). We therefore conclude that PAb could be used for the effective screening and identification of TAA. PAb may have certain anti-tumor functions in vitro and in vivo. As such, its combination with proteomic technologies could be a promising approach for sieving TAA for the diagnosis and therapy of MM.